An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects

Status:   Recruiting

Code: ITL-022-HCC-BKK-VAX+S

Type: Phase II , Open Label

Experimental Product: AlloVax®

Indication: Advanced or Recurrent Hepatocellular Carcinoma (Liver Cancer)

Principal Investigator: Wirote Launsoontornsiri, MD

Location: National Cancer Institute of Thailand (Bangkok)

SPECIALITY INFORMATION

patients


Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals


Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more

Investors


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more